Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Arcus Biosciences Inc
Astellas Pharma Inc
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
Celldex Therapeutics Inc
Daiichi Sankyo Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
F1 Oncology Inc
Genosco Inc
HEC Pharm Co Ltd
Hope Biosciences Inc
Incyte Corp
Konruns Pharmaceutical Co Ltd
Mirati Therapeutics Inc
Novithera SAS
Ono Pharmaceutical Co Ltd
Oribase Pharma
Qurient Co Ltd
Rigel Pharmaceuticals Inc
SiglChem Lifesciences Corp
Symphogen A/S
Takeda Pharmaceutical Co Ltd
TamRx LLC
Tolero Pharmaceuticals Inc
Vichem Chemie Research Ltd
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bemcentinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kise Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by BerGenBio ASA, H2 2019
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by F1 Oncology Inc, H2 2019
Pipeline by Genosco Inc, H2 2019
Pipeline by HEC Pharm Co Ltd, H2 2019
Pipeline by Hope Biosciences Inc, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Konruns Pharmaceutical Co Ltd, H2 2019
Pipeline by Mirati Therapeutics Inc, H2 2019
Pipeline by Novithera SAS, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by Oribase Pharma, H2 2019
Pipeline by Qurient Co Ltd, H2 2019
Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Pipeline by SignalChem Lifesciences Corp, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by TamRx LLC, H2 2019
Pipeline by Tolero Pharmaceuticals Inc, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019